IP Library Granted Patent US 7,300,754
Granted Patent B2
US 7,300,754 · App. 10/830,454 · Granted Nov 27, 2007

Methods for detecting the presence of or predisposition to autosomal dominant hypercholesterolemia

Assignee: Institut National de la Sante et de la Recherche Medicale
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,300,754
App. No.
10/830,454
Granted
Nov 27, 2007
Kind
B2
Abstract

The present invention discloses the identification of a human hypercholesterolemia causal gene, which can be used for the diagnosis, prevention and treatment of hypercholesterolemia, more particularly familial hypercholesterolemia, as well as for the screening of therapeutically active drugs. The invention more specifically disclosed that mutations in the PCSK9 gene encoding NARC-1 causes autosomal dominant hypercholesterolemia and represent novel targets for therapeutic intervention. The invention can be used in the diagnosis of predisposition to, detection, prevention and/or treatment of coronary heart disease and, cholesterol, lipid and lipoprotein metabolism disorders, including familial hypercholesterolemia, atherogenic dyslipidemia, atherosclerosis, cardiovascular diseases.

Claims (5)

1. A method of detecting the presence of or predisposition to autosomal dominant hypercholesterolemia in a human subject, the method comprising (i) providing a nucleic acid sample comprising a PCSK9 nucleic acid sequence from the subject and (ii) detecting the presence of an alteration in the PCSK9 nucleic acid sequence, the alteration being a T→A or T→G substitution at nucleotide 625 of SEQ ID NO:1, said alteration in said nucleic acid sequence being indicative of the presence of or predisposition to autosomal dominant hypercholesterolemia.

2. The method according to claim 1 , wherein said alteration leads to a decrease in expression of the N2 form of NARC-1 encoded by the PCSK9 nucleic acid sequence.

3. The method according to claim 1 , wherein said alteration is a T→A substitution at nucleotide 625 of SEQ ID NO: 1.

4. The method according to claim 2 , wherein said alteration in the nucleic acid is one which encodes for an amino acid substitution of a Serine at position 127.

5. The method according to claim 2 , wherein said alteration in the nucleic acid is one which encodes for an amino acid substitution of a Serine at position 127 by an Arginine.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2004
From: ABI FADEL, MARIANNE; BOILEAU, CATHERINE; RABES, JEAN-PIERRE; SEIDAH, NABIL G.; VARRET, MATHILDE
To: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Reel/Frame 015638/0686 →
Priority Claims (1)
EP 03291025 · Apr 25, 2003 · regional
Continuity (2)
Provisional Application 6053823100 · Jan 23, 2004
Related Publication 20040248177A1 · Dec 9, 2004